Longeveron (LGVN) Operating Margin Growth (1y) (2021 - 2026)

Longeveron (LGVN) Operating Margin Growth (1y) (2021 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Operating Margin Growth (1y) (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 1,552.00
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 1,536.00
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -170.00
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 1,276.00
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Longeveron 14.87 Bn 14.86 Bn 264,000.00 16,009.00

Historic Data

Download Data
DateValue
Mar 31, 2026 16,009.00
Dec 31, 2025 -76,923.00
Sep 30, 2025 -473,434.00
Jun 30, 2025 -96,005.00
Mar 31, 2025 -61,349.00
Dec 31, 2024 792,497.00
Sep 30, 2024 283,924.00
Jun 30, 2024 188,439.00
Mar 31, 2024 94,397.00
Dec 31, 2023 -430,352.00
Sep 30, 2023 174,633.00
Jun 30, 2023 -172,646.00
Mar 31, 2023 -59,548.00
Dec 31, 2022 -240,222.00
Sep 30, 2022 -307,278.00
Jun 30, 2022 12,938.00
Mar 31, 2022 -17,516.00
Sep 30, 2021 -206,286.00
Jun 30, 2021 -62,651.00
Mar 31, 2021 -90,721.00